Form 4: 5AM Partners Plans Future Skye Bioscience Share Sales

Investment funds associated with 5AM Partners have reported planned sales of Skye Bioscience common shares for August 2025.

Summary

• 5AM Partners VII, LLC and related entities, including 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P., have reported planned sales of Skye Bioscience, Inc. common stock.
• On August 21, 2025, 5AM Ventures II, L.P. plans to sell 58,642 shares at a weighted average price of $3.57 per share, and 5AM Co-Investors II, L.P. plans to sell 2,314 shares at the same price.
• On August 22, 2025, 5AM Ventures II, L.P. plans to sell 163,979 shares at a weighted average price of $3.42 per share, and 5AM Co-Investors II, L.P. plans to sell 6,470 shares at the same price.
• The planned sales on August 21, 2025, are expected to occur within a price range of $3.55 to $3.69.
• The planned sales on August 22, 2025, are expected to occur within a price range of $3.30 to $3.59.
• Following these planned transactions, 5AM Ventures II, L.P. is expected to beneficially own 1,457,064 shares and 5AM Co-Investors II, L.P. is expected to beneficially own 57,493 shares.
• 5AM Ventures VII, L.P. currently beneficially owns 8,167,206 shares.

Sentiment

Score: 4

Explanation: The filing reports planned future sales of common stock by a 10% owner and entities affiliated with directors. While these are not immediate transactions, the intent to divest a significant number of shares, particularly without explicitly being under a 10b5-1 plan, can be perceived as a cautious or negative signal by the market regarding future valuation or prospects.

Negatives

• The filing indicates an intent by a significant 10% owner and entities affiliated with directors to reduce their holdings in Skye Bioscience through future sales.
• The planned sales are not explicitly stated to be pursuant to a Rule 10b5-1 trading plan, which could imply discretionary selling intent.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sales of common stock are planned by investment funds (5AM Ventures II, L.P., 5AM Co-Investors II, L.P.) where managing members (Dr. John Diekman, Dr. Scott M. Rocklage, Dr. Kush Parmar, Andrew J. Schwab) are also directors or affiliated with 10% owners of Skye Bioscience, Inc.

Stakeholder Impact

• Shareholders: Potential negative sentiment due to the signal of future insider selling, which could put downward pressure on the stock price as the market anticipates these transactions.
• Management: May face questions regarding the reasons for the planned divestment by significant investors and directors.

Key Dates

Recommendation

The reported planned future sales by a significant institutional investor and affiliated directors suggest an intent to reduce exposure to Skye Bioscience. While these are not immediate transactions, the signal of future divestment, especially not explicitly under a 10b5-1 plan, warrants a cautious 'hold' recommendation for existing investors, suggesting a wait-and-see approach before further investment or divestment.

Keywords

Skye Bioscience, SKYE, 5AM Partners, insider selling, Form 4, beneficial ownership, institutional investor, planned stock sale